Initially, the difference in IL-33 levels within the tumour microenvironment of the primary and metastatic carcinomas was the clue that led us to study ILC2s, whose development and function are strongly dependent on IL-33 expression11,19,45. The gene discussed is IL33; the disease is metastatic carcinoma.